Rezolute Bio develops therapies for rare diseases, aiming to address unmet needs in both pediatric and adult patients. Its lead candidate, RZ358, is a human monoclonal antibody in late-stage trials for congenital hyperinsulinism and works by binding to and inhibiting insulin to reduce hypoglycemic events. The company also pursues RZ402, an oral plasma kallikrein inhibitor for diabetic macular edema. Its goal is to bring approved therapies to patients by advancing late-stage programs toward commercialization and building a portfolio focused on rare diseases.
Company Size
51-200
Company Stage
IPO
Headquarters
Louisville, Kentucky
Founded
2010
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?